CN1055015C - Weijisan for gastropathy - Google Patents
Weijisan for gastropathy Download PDFInfo
- Publication number
- CN1055015C CN1055015C CN97107733A CN97107733A CN1055015C CN 1055015 C CN1055015 C CN 1055015C CN 97107733 A CN97107733 A CN 97107733A CN 97107733 A CN97107733 A CN 97107733A CN 1055015 C CN1055015 C CN 1055015C
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- treatment
- gastropathy
- examples
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to medicinal gastropathy powder for curing gastrosis, particularly to for gastritis and peptic ulcers. The present invention is prepared from pure Chinese medicines of galingale, aucklandia root, cuttlebone, zedoary, amomum globosum loureiro, nardostachys root, calcined alum, chicken gizzard skin, coptis, hyacinth bletilla, corydalis tuber, malt, Sinomenium, snakegourd seed and oak bark according to the weight proportion.
Description
The present invention relates to a kind of medicine Weijisan for gastropathy for the treatment of gastropathy, is a kind of compositions of being made by pure Chinese crude drug, is particularly suitable for the medicine as treatment gastritis, peptic ulcer gastropathy such as (containing gastric ulcer and duodenal bulbar ulcer).
Gastropathy, gastritis (shallow harmony in the exterior atrophic) particularly, peptic ulcer (containing gastric ulcer and duodenal bulbar ulcer) is a kind of commonly encountered diseases, frequently-occurring disease, at present, the medicine for the treatment of these diseases is more, the curative effect of the degree of having nothing in common with each other, but generally speaking, curative effect is not ideal enough, relapse rate is higher after the drug withdrawal, with regard to better medicine at present commonly used, its effective percentage is below 80%, and its relapse rate is more than 35%.
Purpose of the present invention just is: invent a kind of composition medicine Weijisan for gastropathy of being made by pure Chinese crude drug for the treatment of gastropathy, to improve the treatment curative effect and to reduce relapse rate.
The present invention realizes its purpose like this: this Weijisan for gastropathy is a kind of compositions of being made by pure Chinese crude drug, its component and proportional quantity, and (%) counts with percentage ratio:
Rhizoma Alpiniae Officinarum 1-6, Radix Aucklandiae 1-6, Os Sepiae 1-6, Rhizoma Curcumae 1-10,
Radix Et Rhizoma Nardostachyos 1-6, Endothelium Corneum Gigeriae Galli 1-6, Amomum globosum loureiro 1-6, dried Alumen 1-6,
Radix Aristolochiae 4-20, Rhizoma Coptidis 2-10, Pseudobulbus Bletillae (Rhizoma Bletillae) 10-40, Rhizoma Corydalis 6-30,
Fructus Hordei Germinatus 1-6, Semen Trichosanthis 2-6, Corium elephatis 4-20, the summation of its each component is 100%.
Further specified below in conjunction with embodiment, but be not limited only to this.
Embodiment one
1, this medicine medical material component and proportional quantity thereof (in percentage ratio %) are:
Rhizoma Alpiniae Officinarum 4, the Radix Aucklandiae 3, Os Sepiae 3, Rhizoma Curcumae 10, Amomum globosum loureiro 1,
Radix Et Rhizoma Nardostachyos 6, dried Alumen 3, Endothelium Corneum Gigeriae Galli 3, Rhizoma Coptidis 3, the Pseudobulbus Bletillae (Rhizoma Bletillae) 10,
Rhizoma Corydalis 11, Fructus Hordei Germinatus 1, Radix Aristolochiae 20, GUAJIANG core 2, Corium elephatis 20,
The summation of its each component is 100%.
2, manufacture method.Identical with the conventional manufacture method of Chinese patent medicine, earlier Chinese crude drug is cleaned, press proportional quantity and measure, well is concocted with conventional concocting method medical material, is ground into powder, powder, also can make pill or capsule-type etc. according to a conventional method, according to quantity with bag or bottled getting final product.
3, protection against the tide is stored in shady and cool dry place.
4, instructions of taking.Various dosage forms, three times on the one, each 2 grams, seriously ill person's four times a day, boiled water is taken after mixing it with water.For gastritis (shallow table or atrophic), 7 is a course of treatment, serve on 2-3 the course of treatment, and for peptic ulcer (containing gastric ulcer and bulboduodenal ulcer), be a course of treatment January, serve on 2-3 the course of treatment.
Taboo: dry peppery, the raw food food such as hard of fasting.
5, clinical effectiveness.
To gastritis (shallow harmony in the exterior atrophic) 166 examples, treat 2-3 the course of treatment after, through hospital's fiber microscopy and biopsy, 115 examples of wherein fully recovering, effective 49 examples, invalid 2 examples, average total effective rate is 98.8%, does not find that toxic and side effects takes place.To peptic ulcer (containing gastric ulcer and duodenal bulbar ulcer) 38 examples, treat 2-3 the course of treatment after, through hospital's fiber microscopy and biopsy, 17 examples of wherein fully recovering, effective 18 examples, invalid 3 examples, average total effective rate is 92.1%, finds no the toxic and side effects reaction.
The treatment standard declaration: recovery from illness refers to that after 2-3 the course of treatment clinical symptom disappearance is through fiber microscopy and biopsy, foci disappearance.Effectively refer to after 2-3 the course of treatment, through fiber microscopy and biopsy, clinical symptom disappearance, the lesion tissue scope is dwindled.Invalid finger is after 2-3 the course of treatment, and clinical symptoms does not have significant change before fiber microscopy and biopsy and treatment.
Embodiment two
1, this medicine medical material component and proportional quantity thereof (in percentage ratio %) are:
Rhizoma Alpiniae Officinarum 6, the Radix Aucklandiae 1, Os Sepiae 1, Rhizoma Curcumae 4, Radix Et Rhizoma Nardostachyos 3,
Dried Alumen 1, Amomum globosum loureiro 6, Radix Aristolochiae 10, Rhizoma Coptidis 2, the Pseudobulbus Bletillae (Rhizoma Bletillae) 13,
Rhizoma Corydalis 30, Fructus Hordei Germinatus 6, Endothelium Corneum Gigeriae Galli 1, Semen Trichosanthis 6, Corium elephatis 10,
The summation of its each component is 100%.
2, manufacture method, preservation, instructions of taking, treatment standard declaration are with example one.
3, clinical effectiveness.
To gastritis 145 examples, treat 2-3 the course of treatment after, through hospital's fiber microscopy and biopsy, 96 examples of wherein fully recovering, effective 47 examples, invalid 2 examples, average total effective rate about 98.6%, to peptic ulcer 35 examples, treat 2-3 the course of treatment after, through hospital's fiber microscopy and biopsy, 14 examples of wherein fully recovering, effective 18 examples, invalid 3 examples, average total effective rate about 91.4%.In the above-mentioned treatment, all do not find toxicity.
Embodiment three
1, this medicine medical material component and proportional quantity thereof (in percentage ratio %) are:
Rhizoma Alpiniae Officinarum 1, the Radix Aucklandiae 6, Os Sepiae 6, Rhizoma Curcumae 1, Radix Et Rhizoma Nardostachyos 1,
Dried Alumen 6, Amomum globosum loureiro 3, Radix Aristolochiae 4, Rhizoma Coptidis 10, the Pseudobulbus Bletillae (Rhizoma Bletillae) 40,
Rhizoma Corydalis 6, Fructus Hordei Germinatus 3, Endothelium Corneum Gigeriae Galli 6, Semen Trichosanthis 3, Corium elephatis 4,
Each component total amount and be 100%.
2, manufacture method, preservation, instructions of taking, treatment standard declaration are with example one.
3, clinical effectiveness.
To gastritis 108 examples, treat 2-3 the course of treatment after, through hospital's fiber microscopy and biopsy, 59 examples of wherein fully recovering, effective 47 examples, invalid 2 examples, average total effective rate about 98.2%.To peptic ulcer 31 examples, treat 2-3 the course of treatment after, through hospital's fiber microscopy and biopsy, 12 examples of wherein fully recovering, effective 16 examples, invalid 3 examples, average total effective rate about 90.3%.In the above clinical treatment, all find no toxicity.
Pharmacology and resultant effect analysis.The Rhizoma Curcumae heat-clearing and toxic substances removing of this medicine with the same usefulness of Rhizoma Coptidis, strengthens heat-clearing toxin-expelling functions, and it is stronger to remove helicobacter pylori strength; Corium elephatis granulation promoting good medicine, dried Alumen is held back skin ulcer, reuses the Pseudobulbus Bletillae (Rhizoma Bletillae), the same usefulness of three flavors, granulation promoting power is grand, and it is remarkable to hold back skin ulcer, promotes the lesion tissue reparation effectively, and well can end digestive tract hemorrhage preferably; Semen Trichosanthis a surname spleen helps circulation of qi promoting intestinal stasis relieving class efficacy of drugs such as Radix Et Rhizoma Nardostachyos more remarkable, has effectively promoted the recovery of gastric motility function, reuses Rhizoma Corydalis, Radix Aristolochiae, fast and effeciently pain relieving.Therefore, comprehensive compatibility, this Chinese patent medicine is heat-clearing and toxic substances removing effectively, removes helicobacter pylori, promotes lesion tissue to repair fast, promotes the fast quick-recovery of gastric motility function, and pain relieving power is strong, can fundamentally reach therapeutic purposes.Find out from above-mentioned treatment, after 2-3 course of therapy, the average total effective rate of gastritis is about 98.5%, peptic ulcer about 91.7% to gastritis 419 examples and peptic ulcer 104 examples.Contrast treatment with similar medicine at present commonly used and show that this medication effect is good, instant effect, the curative effect height, relapse rate is low.Generally for gastritis, observe in 2 years after drug withdrawal, its relapse rate is lower than 13.9% (superficial gastritis), 21.2% (atrophic gastritis); The gastric ulcer recurrence rate is lower than 21.4%, the duodenal bulbar ulcer relapse rate is lower than 26%.
Claims (1)
1, a kind of medicine Weijisan for gastropathy that is used for the treatment of gastropathy is a kind of compositions of being made by pure Chinese crude drug, it is characterized in that: its component and proportional quantity, and (%) counts with percentage ratio:
Rhizoma Alpiniae Officinarum 1-6, Radix Aucklandiae 1-6, Os Sepiae 1-6, Rhizoma Curcumae 1-10,
Radix Et Rhizoma Nardostachyos 1-6, Endothelium Corneum Gigeriae Galli 1-6, Amomum globosum loureiro 1-6, dried Alumen 1-6,
Radix Aristolochiae 4-20, Rhizoma Coptidis 2-10, Pseudobulbus Bletillae (Rhizoma Bletillae) 10-40, Rhizoma Corydalis 6-30,
Fructus Hordei Germinatus 1-6, Semen Trichosanthis 2-6, Corium elephatis 4-20,
The summation of its each component is 100%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97107733A CN1055015C (en) | 1997-10-21 | 1997-10-21 | Weijisan for gastropathy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN97107733A CN1055015C (en) | 1997-10-21 | 1997-10-21 | Weijisan for gastropathy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1178111A CN1178111A (en) | 1998-04-08 |
CN1055015C true CN1055015C (en) | 2000-08-02 |
Family
ID=5169824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97107733A Expired - Fee Related CN1055015C (en) | 1997-10-21 | 1997-10-21 | Weijisan for gastropathy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1055015C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732663B (en) * | 2009-12-30 | 2011-11-02 | 宁波市鄞州奥胜生物科技有限公司 | Rebamipide-containing Chinese and western medicinal composition |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1125642C (en) * | 2000-06-14 | 2003-10-29 | 邓开仲 | Pharmaceutical for treating gastroduodenal ulcer and gastritis, and its prepn. process |
CN101066434B (en) * | 2007-06-05 | 2010-06-16 | 李国� | Omeprazole-containing medicine |
CN101066418B (en) * | 2007-06-05 | 2010-09-01 | 李国� | Medicine containing colloidal bismuth for treating gastric uncer |
CN101926958B (en) * | 2009-12-30 | 2011-12-21 | 宁波市鄞州福瑞达生物科技有限公司 | Chinese and Western medicine composition containing carbenoxolone sodium |
CN101810828B (en) * | 2010-04-15 | 2011-08-31 | 罗丹晓 | Combination medicament containing teprenone |
CN101797364B (en) * | 2010-04-15 | 2011-06-15 | 叶希友 | Marzulene-s-containing combined medicine |
CN105616690A (en) * | 2016-03-17 | 2016-06-01 | 王科兵 | Drug for treating stomach diseases and preparation method thereof |
-
1997
- 1997-10-21 CN CN97107733A patent/CN1055015C/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
辽宁中医杂志18,2 1919.9.1 田羊年,中药萎缩性胃炎100例 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732663B (en) * | 2009-12-30 | 2011-11-02 | 宁波市鄞州奥胜生物科技有限公司 | Rebamipide-containing Chinese and western medicinal composition |
Also Published As
Publication number | Publication date |
---|---|
CN1178111A (en) | 1998-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101066434B (en) | Omeprazole-containing medicine | |
CN100584371C (en) | Chinese-western medicine composition containing carafate for treating gastric ulcer | |
CN100515484C (en) | Iprazole containing medicine | |
CN1055015C (en) | Weijisan for gastropathy | |
CN100515485C (en) | Medicine composition for treating gastric ulcer | |
CN100534516C (en) | Medicine containing rabeprazole for treating gastric ulcer | |
CN1237454A (en) | Health-care medicine with therapeutic action of curing gastropathy and its preparation method | |
CN101926958B (en) | Chinese and Western medicine composition containing carbenoxolone sodium | |
CN100574793C (en) | The medicine that contains ranitidine | |
CN101066418B (en) | Medicine containing colloidal bismuth for treating gastric uncer | |
CN101732663B (en) | Rebamipide-containing Chinese and western medicinal composition | |
CN101732664B (en) | Enprostil-containing Chinese and Western medicinal composition for treating gastric ulcer | |
CN101773645B (en) | Chinese-western medicine composition containing spizofurone | |
CN101797356B (en) | Traditional Chinese medicine and Western medicine composition containing Lafutidine | |
CN101721657B (en) | Chinese and western medicine composition containing licorzinc | |
CN101797359B (en) | Chinese and western medicinal composition containing pantoprazole | |
CN101797357B (en) | Chinese-western medicinal composition containing lansoprazole | |
CN101773646B (en) | Chinese and Western medicine composition containing proglumide | |
CN101797358B (en) | Medicinal composition containing roxatidine | |
CN101797364B (en) | Marzulene-s-containing combined medicine | |
CN101810828B (en) | Combination medicament containing teprenone | |
CN1088365C (en) | Medicine for curing infectious gastrosis and its preparing process | |
CN1121225C (en) | Hepatitis treating medicine | |
CN1236811C (en) | Medicine for curing gastropathy | |
CN1122525C (en) | Medicine for treating gastropathy and preparation process thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |